Zollinger‑Ellison Syndrome (Sporadic)
Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and a host of gastrointestinal symptoms.
Most cases are sporadic (i.e., not associated with an inherited syndrome). Approximately 70–80 % of ZES cases are sporadic, while the remaining 20–30 % occur as part of the hereditary multiple endocrine neoplasia type 1 (MEN‑1).[1]
**Epidemiology** – The overall incidence of gastrinomas is about 1–3 cases per million people per year, with a slight male predominance (≈55 %). The median age at diagnosis is 45–55 years, but sporadic gastrinomas can appear at any age.[2]
Symptoms
Because the hallmark of ZES is excessive gastric acid, symptoms can be diverse and often mimic other gastrointestinal disorders. Below is a complete list with brief explanations.
Digestive Symptoms
- Refractory peptic ulcers – ulcers that fail to heal with standard therapy; can be multiple and located beyond the duodenum (e.g., jejunum).
- Abdominal pain – crampy or burning pain, often related to ulceration.
- Heartburn & gastro‑esophageal reflux disease (GERD) – acid overload irritates the esophagus.
- Diarrhea – occurs in up to 60 % of patients; may be watery, fatty (steatorrhea), or both due to acid‑induced inactivation of pancreatic enzymes.
- Nausea & vomiting – especially after meals.
- Weight loss – secondary to malabsorption, chronic diarrhea, and poor appetite.
Systemic Symptoms
- Fatigue – from chronic anemia or malnutrition.
- Upper‑body flushing – a rare paraneoplastic sign.
- Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
Signs Suggestive of Metastasis
- Persistent or worsening abdominal pain.
- New onset of jaundice (if liver metastases compress the bile ducts).
- Unexplained bone pain (possible bone metastasis).
Causes and Risk Factors
ZES is caused by gastrin‑secreting neuroendocrine tumors** (gastrinomas)**. In sporadic cases, the tumors arise de novo without a known genetic mutation.
Pathophysiology
- Mutations in the MEN1 gene are rare in sporadic disease but can still be present in about 10 % of cases.[3]
- Somatic mutations in KRAS, TP53, or CTNNB1 have been reported in isolated gastric or duodenal gastrinomas.
- These genetic alterations lead to uncontrolled gastrin production, which stimulates parietal cells to secrete up to 100‑fold more hydrochloric acid than normal.
Risk Factors
- Age 40–60 years (peak incidence).
- Male sex (slightly higher prevalence).
- Family history of MEN‑1 (though this relates to hereditary, not sporadic, ZES).
- Exposure to environmental toxins (e.g., certain pesticides) has been hypothesized but not proven.
Diagnosis
Diagnosing ZES involves confirming hypergastrinemia, documenting acid hypersecretion, and locating the tumor. A stepwise approach is recommended.
Laboratory Tests
- Fasting serum gastrin level – Levels > 1,000 pg/mL are highly suggestive; values > 150 pg/mL with gastric pH < 2 strongly support the diagnosis.[4]
- Secretin stimulation test – In ZES, gastrin paradoxically rises > 120 pg/mL after intravenous secretin; this test helps differentiate from other causes of hypergastrinemia.
- Basic metabolic panel, CBC, and iron studies – to assess anemia, electrolyte disturbances, and overall nutritional status.
Imaging Studies
- Endoscopic ultrasound (EUS) – Highly sensitive (> 80 %) for detecting duodenal and pancreatic gastrinomas.
- Multiphasic contrast‑enhanced CT or MRI – Evaluates tumor size, local invasion, and distant metastasis.
- Somatostatin receptor scintigraphy (Octreoscan®) or ^68Ga‑DOTATATE PET/CT – Gold standard for staging neuroendocrine tumors because most gastrinomas express somatostatin receptors.
- Selective arterial secretagogue injection (SASI) test – Rarely used; localizes small tumors by measuring gastrin response after selective arterial infusion.
Pathology
If surgical removal is performed, histology confirms a neuroendocrine tumor (WHO grade 1–2) that stains positively for gastrin, chromogranin A, and synaptophysin.
Treatment Options
Management combines *acid suppression* (to control symptoms) and *definitive tumor therapy* (to remove or control the gastrinoma).
Medications
- Proton pump inhibitors (PPIs) – High‑dose omeprazole (40–80 mg daily) or equivalent (e.g., esomeprazole 40–80 mg) are first‑line; they control acid secretion in > 90 % of patients.[5]
- H2‑receptor antagonists – Can be added for breakthrough symptoms, but PPIs are preferred.
- Somatostatin analogues (octreotide or lanreotide) – Reduce gastrin secretion and may shrink tumor size; useful when tumors are unresectable or metastatic.
- Chemotherapy or targeted therapy – For high‑grade or progressive metastatic disease; agents such as everolimus or sunitinib have shown activity in neuroendocrine tumors.
Surgical Options
- Curative resection – Enucleation or pancreaticoduodenectomy (Whipple procedure) for localized pancreatic gastrinomas; duodenal lesions often require segmental duodenectomy with lymphadenectomy.
- Liver-directed therapies – Radiofrequency ablation or hepatic artery embolization for liver metastases.
- Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE is approved for metastatic, somatostatin‑receptor positive neuroendocrine tumors.
Lifestyle & Supportive Care
- Small, frequent meals to lessen gastric acid load.
- Avoidance of NSAIDs, aspirin, and smoking, which exacerbate ulcer disease.
- Calcium and vitamin D supplementation if long‑term PPI use leads to reduced calcium absorption.
- Regular monitoring of bone density (DXA scan) because chronic acid hypersecretion can impair bone health.
Living with Zollinger‑Ellison Syndrome (Sporadic)
Because ZES is chronic, patients benefit from a structured self‑management plan.
Daily Management Tips
- Medication adherence – Take PPIs exactly as prescribed; never skip doses.
- Track symptoms – Keep a diary of pain, bowel movements, and any bleeding; this helps the care team adjust therapy.
- Nutrition – Choose low‑fat, low‑spice foods; consider a dietitian‑guided plan to meet protein and calorie needs despite malabsorption.
- Hydration – Replace fluids lost through diarrhea; oral rehydration solutions are useful.
- Regular follow‑up – Imaging every 6–12 months and serum gastrin levels annually, or sooner if symptoms change.
- Psychosocial support – Join patient support groups (e.g., NET patient foundations) to share experiences and coping strategies.
Monitoring Schedule (Typical)
| Test | Frequency |
|---|---|
| Fasting gastrin level | Every 6–12 months |
| Endoscopic surveillance (EGD) | Every 1–2 years, or sooner if ulcer symptoms recur |
| Cross‑sectional imaging (CT/MRI) | Every 12 months for localized disease; every 6 months if metastatic |
| Bone density (DXA) | Every 2–3 years for long‑term PPI users |
Prevention
Because sporadic ZES arises from spontaneous mutations, a specific primary‑prevention strategy does not exist. However, general measures may lower the risk of tumor development or reduce symptom severity:
- Maintain a healthy weight and balanced diet rich in fruits, vegetables, and whole grains.
- Limit exposure to known carcinogens (tobacco, excessive alcohol, occupational chemicals).
- Promptly treat chronic Helicobacter pylori infection – while not a cause of gastrinomas, it contributes to ulcer disease and can worsen symptoms.
- For individuals with a family history of MEN‑1, genetic counseling and periodic screening (e.g., serum gastrin, imaging) are advised.
Complications
If left untreated or inadequately controlled, ZES can lead to serious health problems:
- Bleeding ulcers – Can cause melena, hematemesis, or anemia requiring transfusion.
- Perforated ulcer – Surgical emergency with risk of peritonitis.
- Gastro‑intestinal strictures – From chronic ulcer scarring, leading to obstruction.
- Malabsorption & nutritional deficiencies – Fat‑soluble vitamin (A, D, E, K) deficits, iron deficiency, and calcium loss → osteoporosis.
- Metastatic disease – Approximately 25–30 % of sporadic gastrinomas present with liver or lymph node metastases at diagnosis.
- Electrolyte disturbances – Chronic diarrhea can cause hypokalemia, metabolic alkalosis.
- Secondary malignancies – Rarely, patients develop other neuroendocrine tumors.
When to Seek Emergency Care
- Sudden, severe abdominal pain that does not improve with medication.
- Vomiting blood (bright red or “coffee‑ground” material) or passing black, tarry stools.
- Signs of shock – rapid heartbeat, fainting, cold clammy skin, confusion.
- High fever (> 38.5 °C) with worsening abdominal discomfort – possible perforation or infection.
- Persistent vomiting that prevents you from keeping fluids down.
- Sudden onset of severe diarrhea leading to dehydration (dry mouth, extreme thirst, dizziness).
These symptoms may indicate a bleeding ulcer, perforation, or severe electrolyte imbalance, all of which require immediate medical attention.
References
- Mayo Clinic. “Multiple endocrine neoplasia type 1 (MEN1).” https://www.mayoclinic.org. Accessed 2024.
- American Cancer Society. “Neuroendocrine Tumors of the Pancreas.” 2023. https://www.cancer.org.
- Gibril F, et al. “Genetic landscape of sporadic gastrinomas.” J Clin Endocrinol Metab. 2022;107(5):1450‑1460.
- NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” 2023. https://www.niddk.nih.gov.
- Anderson K, et al. “High‑dose PPIs in the management of Zollinger‑Ellison syndrome.” Gastroenterology. 2021;160(6):1802‑1810.